MX2022000525A - Vacunas contra la ehrlichia y composiciones inmunogenicas. - Google Patents

Vacunas contra la ehrlichia y composiciones inmunogenicas.

Info

Publication number
MX2022000525A
MX2022000525A MX2022000525A MX2022000525A MX2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A MX 2022000525 A MX2022000525 A MX 2022000525A
Authority
MX
Mexico
Prior art keywords
ehrlichia
immunogenic compositions
vaccines
adjuvant
immunogenic
Prior art date
Application number
MX2022000525A
Other languages
English (en)
Inventor
Paul J Dominowski
Suman Mahan
Jere W Mcbride
Jason J Millership
Duncan M Mwangi
Sharath Rai
Sharon M Wappel
Original Assignee
Res Found Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Found Dev filed Critical Res Found Dev
Publication of MX2022000525A publication Critical patent/MX2022000525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/29—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Richettsiales (O)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

En la presente se proporcionan composiciones inmunogénicas que se pueden utilizar, en algunos aspectos, para inducir una respuesta inmunitaria contra una Ehrlichia como Ehrlichia canis. En algunas modalidades, la composición inmunogénica comprende una bacterina de E. canis y/o un adyuvante, como por ejemplo una emulsión o un adyuvante liposomal. Asimismo se proporcionan métodos relacionados, como para el diagnóstico o la vacunación contra la ehrlichiosis.
MX2022000525A 2019-07-12 2020-07-13 Vacunas contra la ehrlichia y composiciones inmunogenicas. MX2022000525A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962873843P 2019-07-12 2019-07-12
US201962879762P 2019-07-29 2019-07-29
US202063049476P 2020-07-08 2020-07-08
PCT/US2020/041779 WO2021011456A1 (en) 2019-07-12 2020-07-13 Ehrlichia vaccines and immunogenic compositions

Publications (1)

Publication Number Publication Date
MX2022000525A true MX2022000525A (es) 2022-04-20

Family

ID=71948757

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000525A MX2022000525A (es) 2019-07-12 2020-07-13 Vacunas contra la ehrlichia y composiciones inmunogenicas.

Country Status (10)

Country Link
US (1) US20220356231A1 (es)
EP (1) EP3996741A1 (es)
JP (1) JP2022540197A (es)
CN (1) CN114514238A (es)
AU (1) AU2020314625A1 (es)
BR (1) BR112022000347A2 (es)
CA (1) CA3146842A1 (es)
CL (1) CL2022000086A1 (es)
MX (1) MX2022000525A (es)
WO (1) WO2021011456A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043085A (en) * 1998-08-27 2000-03-28 Research Development Foundation Ehrlichia canis 120-kDa immunodominant antigenic protein and gene
MXPA05004804A (es) * 2002-11-04 2005-12-05 Res Dev Foundation Antigenos de p153 y p156 para el inmunodiagnostico de erliquiosis canina y humana y usos de los mismos.
US20050202046A1 (en) * 2004-03-11 2005-09-15 Wyeth Canine vaccine for protection against ehrlichiosis
US7842474B2 (en) * 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
ES2928463T3 (es) * 2005-04-04 2022-11-18 Idexx Lab Inc DIVA (que diferencia animales infectados de vacunados) de Ehrlichia canis
WO2006138509A2 (en) * 2005-06-16 2006-12-28 Research Development Foundation Immunoreactive protein orthologs of ehrlichia canis and e. chaffeensis
WO2008000070A1 (en) * 2006-06-27 2008-01-03 Wellington Laboratories Inc. Glycyrrhetinic acid derivatives
EP2064231B2 (en) * 2006-08-31 2020-08-26 Research Development Foundation Immunoreactive glycoprotein gp19 of ehrlichia canis
MX368220B (es) * 2008-06-27 2019-09-24 Zoetis Services Llc Composiciones adyuvantes novedosas.
CA2796563C (en) * 2009-04-28 2018-05-22 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
PT2575878T (pt) * 2010-05-28 2018-10-03 Zoetis Belgium S A Vacinas compreendendo colesterol e cpg como moléculas únicas adjuvante-portador
EP2433646A1 (en) * 2010-09-22 2012-03-28 Intervet International BV Vaccine against Ehrlichia canis and associated methods
ES2748205T3 (es) * 2012-05-31 2020-03-13 Zoetis Services Llc Vacunación con coronavirus respiratorio canino para protección contra infecciones por B. Bronchiseptica
CA2924526A1 (en) * 2013-09-19 2015-03-26 Paul Joseph Dominowski Water-in-oil emulsions comprising immunostimulatory oligonucleotides
EP3830105A4 (en) * 2018-07-27 2022-07-27 Research Development Foundation CHIMERIC IMMUNOGENIC POLYPEPTIDES

Also Published As

Publication number Publication date
CN114514238A (zh) 2022-05-17
US20220356231A1 (en) 2022-11-10
WO2021011456A1 (en) 2021-01-21
BR112022000347A2 (pt) 2022-04-12
JP2022540197A (ja) 2022-09-14
AU2020314625A1 (en) 2022-02-03
CL2022000086A1 (es) 2022-09-30
EP3996741A1 (en) 2022-05-18
CA3146842A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
EP3616716A3 (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
PH12017502233A1 (en) Formulations for neoplasia vaccines and methods of preparing thereof
MX2017014538A (es) Regimenes de cebado-refuerzo que implican la administracion de al menos un constructo de arnm.
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
NZ717594A (en) Oil-based adjuvants
WO2017214596A8 (en) Compositions and methods for preventing and treating zika virus infection
BR112016015422A2 (pt) formulações de vacina de frasco único
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
EA201892735A1 (ru) Состав вакцины против hiv
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2016062020A9 (zh) 茯苓多糖活性组分和成分、其制备方法及用途
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
EA201692375A1 (ru) Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов
AU2016248452A8 (en) Bordetella pertussis immunogenic vaccine compositions
EA201892003A1 (ru) Лечение атопического дерматита собак
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
MX2022000525A (es) Vacunas contra la ehrlichia y composiciones inmunogenicas.
MX2018012270A (es) Novedosas formulaciones de vacuna neumococica.
MX2021005303A (es) Composiciones inmunogenicas.
WO2019028396A8 (en) Induction of protective immunity against antigens